About
KAER Biotherapeutics Corporation is a biotechnology company based in Escondido, California, founded in 2008. The company specializes in advanced respiratory aerosol drug delivery platforms aimed at treating life-threatening respiratory conditions in both pediatric and adult patients. Led by CEO Donovan B Yeates, Ph.D., KAER develops two primary aerosol delivery systems: AeroPulsR and SUPRAER-Clinic. These systems enable the rapid administration of high doses of aerosolized therapeutics directly to the distal lungs, addressing critical needs in intensive care units, emergency rooms, and surgical suites. AeroPulsR delivers aqueous aerosols through various modes, while SUPRAER-Clinic focuses on solid particle aerosols. KAER's patented technology allows for the effective delivery of both low- and high-viscosity drug solutions, which is essential for treating respiratory distress. The company is currently in the pre-clinical development phase, with plans for animal study validation by mid-2026. KAER is actively seeking licensing partners to commercialize its innovative products globally, with a mission to reduce mortality rates in patients suffering from respiratory distress.
Technologies
Keywords
Company Information
-
Employees 3
-
Founded 2008
-
Total Funding $2300000
Location
926 S Andreasen Dr, Escondido, California, United States, 92029